Consensus Aptose Biosciences Inc.

Equities

APS

CA03835T3091

Market Closed - Toronto S.E. Other stock markets 03:59:50 2024-04-25 pm EDT			5-day change	1st Jan Change
1.62 ^CAD	-2.41%		-7.43%	-51.64%

12:00am	Certain Warrants of Aptose Biosciences Inc. are subject to a Lock-Up Agreement Ending on 25-APR-2024.	CI
12:00am	Certain Common Shares of Aptose Biosciences Inc. are subject to a Lock-Up Agreement Ending on 25-APR-2024.	CI

Evolution of the average Target Price on Aptose Biosciences Inc.

Price target over the last 5 years

History of analyst recommendation changes

702d0dc2f18c64fbf.cGnfRavFYczW-_k9ocUDArJBrBglZ282kQmZjQhIvO0.EV2IHcKsDKKmlp5z861JOtEZ4GkcUytap1zsuEoYi90cLp4N6q0D_rmVvA~aaf11959d254a7ab98c1bf3f6c73d13a

Analyst Recommendations on Aptose Biosciences Inc.

RBC Cuts Price Target on Aptose Biosciences to $18 From $23, Keeps Outperform, Speculative Risk	Nov. 10	MT
Oppenheimer Adjusts Aptose Biosciences Price Target to $15 From $50, Maintains Outperform Rating	23-08-11	MT
HC Wainwright & Co. Adjusts Price Target on Aptose Biosciences to $23 From $12, Maintains Buy Rating	23-08-11	MT
RBC Cuts Price Target on Aptose Biosciences to $23 From $40, Keeps Outperform Rating, Speculative Risk Qualifier	23-08-11	MT
Piper Sandler Initiates Aptose Biosciences at Overweight Rating With $37 Price Target	23-06-12	MT
Oppenheimer Adjusts Aptose Biosciences Price Target to $50 From $9, Maintains Outperform Rating	23-06-12	MT
Piper Sandler Adjusts Aptose Biosciences' Price Target to $37 From $45, Keeps Overweight Rating	23-06-07	MT
RBC Adjusts Price Target on Aptose Biosciences to $40 From $75 Amid Reverse Stock Split, Keeps Outperform, Speculative Risk	23-06-07	MT
RBC Capital Maintains Outperform/Speculative Rating, US$5 Target on Aptose Biosciences After Q1	23-05-09	MT
Canaccord Genuity Adjusts Aptose Biosciences Price Target to $8 From $13, Maintains Buy Rating	23-03-27	MT
RBC Trims Aptose Biosciences' Price Target to $5 From $6, Keeps Outperform Rating, Speculative Risk Qualifier	22-11-02	MT
RBC Capital Maintains Outperform/Speculative Risk Rating, US$6 TP on Aptose Biosciences After CFO Appointment	22-06-28	MT
RBC Cuts Price Target on Aptose Biosciences to $6 From $7, Maintains Outperform Rating, Speculative Risk Qualifier	22-05-10	MT
RBC Capital Keeps Outperform/Speculative Risk, US$7 TP on Aptose Biosciences After Q4 Results	22-03-23	MT
RBC Capital Keeps Outperform/Speculative Risk Rating, US$7 TP on Aptose Biosciences	22-01-11	MT
RBC Cuts Price Target on Aptose Biosciences to $7 From $9, Maintains Outperform Rating, Speculative Risk Qualifier	22-01-06	MT
HC Wainwright Adjusts Aptose Biosciences' Price Target to $12 From $14, Keeps Buy Rating	21-12-21	MT
RBC Capital Reiterates Outperform/Speculative Risk Rating, US$9 TP on Aptose Biosciences	21-12-14	MT
RBC Capital Markets Keeps Rating on Aptose Biosciences Unchanged After "Uneventful" Q3 Earnings Call	21-11-12	MT
HC Wainwright Adjusts Aptose Biosciences' Price Target to $14 From $9, Reiterates Buy Rating	21-11-12	MT
APTOSE BIOSCIENCES : Royal Bank Keeps Outperform/Speculative Risk Rating, US$9 TP on Aptose Biosciences	21-08-04	MT
APTOSE BIOSCIENCES : RBC Capital Keeps Outperform/Speculative Risk Rating, US$9 TP on Aptose Biosciences	21-06-11	MT
APTOSE BIOSCIENCES : RBC Capital Keeps Outperform/Speculative Risk, US$9 TP on Aptose Biosciences	21-03-24	MT
APTOSE BIOSCIENCES : Oppenheimer Adjusts Aptose Biosciences PT to $9 From $8, Maintains Outperform Rating	21-03-24	MT
APTOSE BIOSCIENCES : Oppenheimer Adjusts Price Target on Aptose Biosciences to $8 From $9, Maintains Outperform Rating	20-12-07	MT